The following words and phrases when used in this chapter
shall have the meanings given to them in this section unless the
context clearly indicates otherwise:
"Department." The Department of Drug and Alcohol Programs of
the Commonwealth.
"FDA." The United States Food and Drug Administration.
"Non-narcotic opioid treatment." Treatment for opioid
dependence using an FDA-approved drug, including a full opioid
antagonist, offered in a primary care setting. The term does not
include office-based opioid treatment.
"Non-narcotic opioid treatment provider." A health care
practitioner as defined in section 103 of the act of July 19,
1979 (P.L.130, No.48), known as the Health Care Facilities Act,
who provides non-narcotic opioid treatment to at least 100
opioid-addicted patients over an aggregate period.
"Office-based opioid treatment." Treatment for opioid
dependence using a Schedule III, IV or V controlled substance
narcotic, including a partial opioid antagonist, offered in a
primary care setting.
"Office-based opioid treatment provider." A health care
practitioner as defined in section 103 of the Health Care
Facilities Act, who is permitted to provide office-based opioid
treatment under 21 U.S.C. § 823(g)(2)(A) (relating to
registration requirements) to at least 100 opioid-addicted
patients over an aggregate period.
"Opioid." As defined in section 5202 (relating to
definitions).
"Opioid treatment." Treatment provided at a health care
facility as defined in section 5202 that uses pharmacological
interventions, including full opiate antagonist medications to
20190SB0191PN0147 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30